Bénéfices/risques, pratiques professionnelles et approche médico-économique du nivolumab et Cancer du Poumon Non à Petites Cellules (CBNPC)

Françoise Grudé, Romain Corre, Thierry Urban (), Muriel Travers (), Fanny Marhuenda and Delphine Deniel Lagadec
Additional contact information
Françoise Grudé: Observatoire dédié au Cancer
Romain Corre: Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Thierry Urban: CHU Angers - Centre Hospitalier Universitaire d'Angers - UNAM - PRES Université Nantes Angers Le Mans
Muriel Travers: Nantes Univ - Nantes Université
Fanny Marhuenda: Observatoire dédié au Cancer
Delphine Deniel Lagadec: Observatoire dédié au Cancer

Post-Print from HAL

Date: 2018-11-29
References: Add references at CitEc
Citations:

Published in XVIIèmes Journées du GPCO, Groupe de Pharmacologie Clinique Oncologique, Nov 2018, Villejuif, France

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-04489834

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().